gIcare pharma Inc.
Montréal, Québec, H4A 2X8
CEO: Maxime Ranger
+1 514 508 7014
gIcare Pharma develops an innovative, orally-administered drug, GIC-1001, which provides colonic analgesia without the limitations and disadvantages of currently used agents. This new chemical entity is an opioid agonist capable of releasing hydrogen sulphide (H2S), a gaseous mediator providing multiple beneficial pharmacological effects. GIC-1001’s opioid agonist moiety induces viscerosensitivity modulation and exerts antinociceptive effects, which reduces the perception of pain caused by mechanical stimuli in the colon, such as colorectal distension and spasms.
Forbion contact: Sander van Deventer MD Ph.D.